Merck
2Q Revenues: $11.8 billion (+12%)
2Q Earnings: $2.7 billion (+56%)
YTD Revenues: $22.6 billion (+10%)
YTD Earnings: $5.5 billion (earnings were $2.5 billion YTD18)
Comments: KEYTRUDA sales were up 58% in the quarter to $2.6 billion. Human Health Vaccines sales were up 33% to $2.0 billion. JANUVIA / JANUMET sales were down 6% to $1.4 billion.
GARDASIL / GARDASIL 9 sales were up 46% to $886 million. PROQUAD, M-M-R II and VARIVAX sales were up 58% to $675 million. BRIDION sales were up 16% to $278 million. ISENTRESS / ISENTRESS HD sales were down 19% to $247 million. ZETIA / VYTORIN sales were down 39% to $232 million.